Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fibroid treatment showdown: surgery or embolization for better baby chances?

NCT ID NCT02577055

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two treatments for symptomatic uterine fibroids—surgery (myomectomy) and a minimally invasive procedure (uterine artery embolization)—to see which one better helps women get pregnant and have a live birth. It included 9 women aged 18 to 43 with fibroids larger than 3 cm who wanted to conceive. The main goal was to count live births within one year of trying to get pregnant, starting 6 months after treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

9 people

The number who actually took part.

Started

Apr 2016

Finished

Oct 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 43 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged ≥ 18 and ≤ 43 years old * At least one interstitial fibroid more than 3 cm on MRIat MRI) * with symptoms: genital bleeding, chronic pelvic pain or heaviness, anemia, or infertility \> 1 year. * With immediate desire to conceive * without assisted reproductive indication: no tubal infertility, menstrual irregularities, hydrosalpinx, endometriosis, adenomyosis, or male infertility. * Patient with health insurance, who can read and understand French and who has given written consent Exclusion Criteria: * Ongoing regnancy * Emergency Situation * Contraindication to surgery or uterine embolization: allergy to contrast medium , renal failure, immunodeficiency, contraindication to anesthesia, subserosal or submucosal pedunculated fibroids, fibroids with largest diameter inside of the uterine cavity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Leiomyoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leiomyoma uterine corpus leiomyoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Leiomyoma

Contacts and locations

Locations

  • Département de Médecine de la Reproduction, Centre Hospitalier Régionnal Universitaire de Montpellier

    Montpellier, 34000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.